Clinical Trial Update: Safety Study of XmAb®2513 to Treat Hodgkin Lymphoma or Anaplastic Large Cell Lymphoma [Phase 1]

View source ↗

Summary

A Phase 1 safety trial evaluating XmAb2513 for Hodgkin lymphoma and Anaplastic Large Cell Lymphoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anaplastic Large Cell Lymphoma
• Hodgkin Lymphoma

Drugs mentioned

• XmAb2513

Snippet

Sponsor: Xencor, Inc. | Conditions: Hodgkin Lymphoma, Anaplastic Large Cell Lymphoma | Phase 1 | Status: COMPLETED